Bromodomain Factor 5 as a Target for Antileishmanial Drug Discovery
C. N. Russell, J. L. Carter, J. M. Borgia, J. Bush, F. Calderon, R. Gabarro, S. J. Conway, J. C. Mottram, A. J. Wilkinson, N. G. Jones
This paper identifies LdBDF5 as a potential drug target for antileishmanial therapy by showing its interaction with human bromodomain inhibitors and demonstrating antipromastigote activity of SGC-CBP30.
bioRxiv · Aug 21, 2023Biochemistry